Free Trial
OTCMKTS:NVZMY

Novozymes A/S (NVZMY) Stock Price, News & Analysis

Novozymes A/S logo
$67.65 +0.91 (+1.36%)
As of 11/13/2026 03:59 PM Eastern

About Novozymes A/S Stock (OTCMKTS:NVZMY)

Advanced

Key Stats

Today's Range
$67.36
▼
$68.04
50-Day Range
$62.09
▼
$71.93
52-Week Range
$49.90
▼
$75.27
Volume
23,967 shs
Average Volume
42,425 shs
Market Capitalization
$28.04 billion
P/E Ratio
40.03
Dividend Yield
0.58%
Price Target
N/A
Consensus Rating
Buy

Company Overview

Novozymes A/S was a Denmark-based biotechnology company that developed and produced enzymes and microorganisms for industrial and consumer applications. Its solutions were used in areas including household care, food and beverages, agriculture, animal health and bioenergy.

The company’s products included enzymes used in detergents, baking, brewing and biofuel production, as well as microbial solutions for agricultural and other industrial processes. Novozymes served customers in markets around the world.

In January 2024, Novozymes merged with Danish bioscience company Chr. Hansen to form Novonesis. Novozymes’ former businesses became part of the combined company.

AI Generated. May Contain Errors.

Novozymes A/S Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
39th Percentile Overall Score

NVZMY MarketRank™: 
1.95232466509 of 5 stars

Novozymes A/S scored higher than 39% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Novozymes A/S has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 strong buy ratings, no buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Novozymes A/S has received no research coverage in the past 90 days.

  • Read more about Novozymes A/S's stock forecast and price target.
  • Earnings Growth

    Earnings for Novozymes A/S are expected to grow by 7.76% in the coming year, from $2.45 to $2.64 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Novozymes A/S is 40.03, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 26.40.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Novozymes A/S is 40.03, which means that it is trading at a more expensive P/E ratio than the Materials sector average P/E ratio of about 27.61.

  • Price to Earnings Growth Ratio

    Novozymes A/S has a PEG Ratio of 2.99. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Novozymes A/S has a P/B Ratio of 2.58. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.00% of the float of Novozymes A/S has been sold short.
  • Short Interest Ratio / Days to Cover

    Novozymes A/S has a short interest ratio ("days to cover") of 0.19, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Novozymes A/S has recently decreased by 26.95%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Novozymes A/S has a dividend yield of 0.58%, which is in the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Novozymes A/S does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of Novozymes A/S is 23.08%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Dividend Sustainability

    Based on earnings estimates, Novozymes A/S will have a dividend payout ratio of 14.77% next year. This indicates that Novozymes A/S will be able to sustain or increase its dividend.

  • Read more about Novozymes A/S's dividend.
    Receive NVZMY Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for Novozymes A/S and its competitors with MarketBeat's FREE daily newsletter.

    SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

    NVZMY Stock News Headlines

    Top Trader Reveals Stunning Black Friday Deal
    Others paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Trading's Thomas Wood calls it one of the firm's most powerful proprietary trading indicators, and says the company has never run a deal like this before. There are no strings attached, just a steep Black Friday discount on a tool built for traders.tc pixel
    Novozymes A/S (NVZMY) Q2 2026 Earnings Call Transcript
    Novonesis (Novozymes) B ADR NVZMY
    Novozymes AS DRC (NVZMY)
    See More Headlines

    NVZMY Stock Analysis - Frequently Asked Questions

    Novozymes A/S's stock was trading at $63.95 on January 1st, 2026. Since then, NVZMY stock has increased by 5.8% and is now trading at $67.65.

    Novozymes A/S (OTCMKTS:NVZMY) posted its earnings results on Thursday, November, 5th. The biotechnology company reported $0.48 earnings per share for the quarter, missing the consensus estimate of $0.74 by $0.26. The biotechnology company earned $1.28 billion during the quarter, compared to analyst estimates of $1.28 billion. Novozymes A/S had a net margin of 15.59% and a trailing twelve-month return on equity of 6.56%.

    Novozymes A/S subsidiaries include these companies: PrecisionBiotics Group Limited, OrganoBalance GmbH, Pacific Vet Group-USA, Allopartis, TJ Technologies, Iogen Bio-Products, Natural Industries, and others.

    Shares of NVZMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

    Based on aggregate information from My MarketBeat watchlists, some other companies that Novozymes A/S investors own include NVIDIA (NVDA), Novo Nordisk A/S (NVO), Procter & Gamble (PG), AT&T (T), Nestle (NSRGY), Alphabet (GOOG) and Accenture (ACN).

    Company Calendar

    Last Earnings
    11/05/2026
    Today
    11/15/2026
    Fiscal Year End
    12/31/2026

    Industry, Sector and Symbol

    Stock Exchange
    OTCMKTS
    Sector
    Materials
    Industry
    Chemicals
    Sub-Industry
    N/A
    Current Symbol
    OTCMKTS:NVZMY
    Previous Symbol
    OTC:NVZMY
    CIK
    1131345
    Employees
    10,933
    Year Founded
    2000

    Profitability

    EPS (Trailing Twelve Months)
    $1.69
    Trailing P/E Ratio
    40.03
    Forward P/E Ratio
    25.63
    P/E Growth
    2.99
    Net Income
    $660.28 million
    Net Margins
    15.59%
    Pretax Margin
    18.82%
    Return on Equity
    6.56%
    Return on Assets
    4.37%

    Debt

    Debt-to-Equity Ratio
    0.25
    Current Ratio
    1.74
    Quick Ratio
    1.04

    Sales & Book Value

    Annual Sales
    $4.70 billion
    Price / Sales
    5.96
    Cash Flow
    $1.70 per share
    Price / Cash Flow
    39.79
    Book Value
    $26.23 per share
    Price / Book
    2.58

    Miscellaneous

    Outstanding Shares
    414,555,000
    Free Float
    N/A
    Market Cap
    $28.04 billion
    Optionable
    Not Optionable
    Beta
    0.86

    Social Links

    Don't Wait for the OpenAI IPO Cover

    The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

    Get This Free Report

    This page (OTCMKTS:NVZMY) was last updated on 11/13/2026 by MarketBeat.com Staff.
    From Our Partners